↓ Skip to main content

Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis

Overview of attention for article published in Therapeutic Advances in Musculoskeletal Disease, April 2021
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter
7 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
12 Mendeley
Title
Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis
Published in
Therapeutic Advances in Musculoskeletal Disease, April 2021
DOI 10.1177/1759720x211009020
Pubmed ID
Authors

Ahmad Y. Abuhelwa, David J. R. Foster, Arkady Manning-Bennett, Michael J. Sorich, Susanna Proudman, Michael D. Wiese, Ashley M. Hopkins

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 2 17%
Researcher 2 17%
Professor 1 8%
Professor > Associate Professor 1 8%
Student > Postgraduate 1 8%
Other 0 0%
Unknown 5 42%
Readers by discipline Count As %
Medicine and Dentistry 5 42%
Psychology 1 8%
Biochemistry, Genetics and Molecular Biology 1 8%
Unknown 5 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2023.
All research outputs
#7,034,411
of 24,749,767 outputs
Outputs from Therapeutic Advances in Musculoskeletal Disease
#156
of 430 outputs
Outputs of similar age
#146,700
of 433,183 outputs
Outputs of similar age from Therapeutic Advances in Musculoskeletal Disease
#8
of 26 outputs
Altmetric has tracked 24,749,767 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 430 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 433,183 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.